Treatments of Alzheimer’s Disease: A Review
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3713Keywords:
Alzheimer's Disease, Treatment, Accessibility, CostAbstract
Alzheimer’s Disease (AD) affects about 24 million people worldwide and costs Americans billions of dollars every year.1 With the prevalence of AD, treatments are needed to combat the disease and reduce its effect. In the past, cholinesterase inhibitors were used to treat the symptoms of the disease. In recent years, however, a new type of drug, monoclonal antibody, has been used for the treatment of AD. The purpose of this paper is to review the old and new Alzheimer’s treatment through the lens of affordability and accessibility, and provide insight into the future of the treatment options. In the end, innovative treatments such as vaccines and targeting different mechanisms of action are the next step in Alzheimer’s treatment. Access to these treatments should be more readily available and affordable to low-income families. To support this, the FDA should modify its accelerated approval program to reward rigorous scientific research.
Downloads
References or Bibliography
Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a006239. doi: 10.1101/cshperspect.a006239. PMID: 22908189; PMCID: PMC3405821.
Alzheimer's Association. (2022). 2022 Alzheimer’s Disease Facts and Figures - Alzheimer's Association. Alzheimer's Association. Retrieved September 1, 2022, from https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
Wong, W. (2020). Economic Burden of Alzheimer Disease and Managed Care Considerations. AJMC. Retrieved August 31, 2022, from https://www.ajmc.com/view/economic-burden-of-alzheimer-disease-and-managed-care-considerations#:~:text=Alzheimer%20disease%20is%20the%20most,trillion%20as%20the%20population%20ages
Standridge J. B. (2004). Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinical therapeutics, 26(5), 615–630. https://doi.org/10.1016/s0149-2918(04)90064-1
Alzheimer's Association. (n.d.). Milestones. Alzheimer's Disease and Dementia. Retrieved August 31, 2022, from https://www.alz.org/alzheimers-dementia/research_progress/milestones
Mayeux, R., & Sano, M. (1999). Treatment of Alzheimer's disease. The New England journal of medicine, 341(22), 1670–1679. https://doi.org/10.1056/NEJM199911253412207
Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., & Gracon, S. I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA, 271(13), 985–991.
Brodaty, H. (1996). Tacrine in the Treatment of Alzheimer's Disease. NPS MedicineWise. Retrieved August 31, 2022, from https://www.nps.org.au/australian-prescriber/articles/tacrine-in-the-treatment-of-alzheimers-disease#:~:text=The%20significant%20placebo%20response%20should,home%20care%20by%20delaying%20admission
Gracon, S. I., Knapp, M. J., Berghoff, W. G., Pierce, M., DeJong, R., Lobbestael, S. J., Symons, J., Dombey, S. L., Luscombe, F. A., & Kraemer, D. (1998). Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer disease and associated disorders, 12(2), 93–101. https://doi.org/10.1097/00002093-199806000-00007
Rogers, S. L., & Friedhoff, L. T. (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. British journal of clinical pharmacology, 46 Suppl 1(Suppl 1), 1–6. https://doi.org/10.1046/j.1365-2125.1998.0460s1001.x
Medical Team, Q. M. D. (2021). Aricept (Donepezil)– Information, Dosage, Cost Without Insurance. QuickMD. Retrieved August 31, 2022, from https://quick.md/blog/drugs-information-prices/aricept-donepezil-information-dosage-cost-without-insurance/
Exelon - Food and Drug Administration. U.S. Food and Drug Administration. (n.d.). Retrieved September 1, 2022, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf
Mayo Foundation for Medical Education and Research. (2022, June 1). Rivastigmine (oral route) proper use. Mayo Clinic. Retrieved August 31, 2022, from https://www.mayoclinic.org/drugs-supplements/rivastigmine-oral-route/proper-use/drg-20065860#:~:text=Adults%E2%80%94At%20first%2C%201.5%20milligrams,mg%20two%20times%20a%20day
Rivastigmine Coupons & Prices. SingleCare. (n.d.). Retrieved August 31, 2022, from https://www.singlecare.com/prescription/rivastigmine
Coyle, J., & Kershaw, P. (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biological psychiatry, 49(3), 289–299. https://doi.org/10.1016/s0006-3223(00)01101-x
Mayo Foundation for Medical Education and Research. (2022, August 1). Galantamine (oral route) side effects. Mayo Clinic. Retrieved August 31, 2022, from https://www.mayoclinic.org/drugs-supplements/galantamine-oral-route/side-effects/drg-20067458?p=1#:~:text=Galantamine%20is%20used%20to%20treat,the%20disease%20from%20getting%20worse
Razay, G., & Wilcock, G. K. (2008). Galantamine in Alzheimer's disease. Expert review of neurotherapeutics, 8(1), 9–17. https://doi.org/10.1586/14737175.8.1.9
Kalola UK, Nguyen H. Galantamine. [Updated 2022 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574546/
U.S. National Library of Medicine. (2020). Galantamine: Medlineplus drug information. MedlinePlus. Retrieved August 31, 2022, from https://medlineplus.gov/druginfo/meds/a699058.html#:~:text=Galantamine%20comes%20as%20a%20tablet,a%20day%20in%20the%20morning
Callaghan, B. C., Reynolds, E., Banerjee, M., Kerber, K. A., Skolarus, L. E., Magliocco, B., Esper, G. J., & Burke, J. F. (2019). Out-of-pocket costs are on the rise for commonly prescribed neurologic medications. Neurology, 92(22), e2604–e2613. https://doi.org/10.1212/WNL.0000000000007564
InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Alzheimer's disease: Does memantine help? 2011 Jul 5 [Updated 2017 Jun 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279356/
U.S Food and Drug Administration. (n.d.). Namenda® Tablets/oral solution (memantine hydrochloride) description. Retrieved September 1, 2022, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021627lbl.pdf
U.S. National Library of Medicine. (2016). Memantine: Medlineplus drug information. MedlinePlus. Retrieved August 31, 2022, from https://medlineplus.gov/druginfo/meds/a604006.html#:~:text=Memantine%20comes%20as%20a%20tablet,day%20with%20or%20without%20food
CMS finalizes Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of alzheimer's disease. CMS. (2022). Retrieved August 31, 2022, from https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment
Commissioner, O. of the. (2021). FDA grants accelerated approval for alzheimer's drug. U.S. Food and Drug Administration. Retrieved August 31, 2022, from https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
Cameron, K. (2022). What You Need to Know About Aduhelm. The National Council on Aging. Retrieved August 31, 2022, from http://ncoa.org/article/what-you-need-to-know-about-aduhelm
FDA. (2021). Highlights of prescribing information. Retrieved September 1, 2022, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf
Arthur, R. (2021, December 21). Biogen halves price of Aduhelm in the US. BioPharma. Retrieved August 31, 2022, from https://www.biopharma-reporter.com/Article/2021/12/21/Biogen-halves-price-of-Aduhelm-in-the-US
Belluck, P., Kaplan, S., & Robbins, R. (2021, July 20). How an unproven alzheimer's drug got approved. The New York Times. Retrieved August 31, 2022, from https://www.nytimes.com/2021/07/19/health/alzheimers-drug-aduhelm-fda.html
Latest findings on Lecanemab - clinical efficacy, ARIA rates, biomarkers relationship to clinical outcomes and dosing regimens . Biogen. (2022). Retrieved August 31, 2022, from https://investors.biogen.com/news-releases/news-release-details/latest-findings-lecanemab-clinical-efficacy-aria-rates#:~:text=Lecanemab%20selectively%20binds%20to%20neutralize,the%20progression%20of%20the%20disease
U.S. Department of Health and Human Services. (2021). How is alzheimer's disease treated? National Institute on Aging. Retrieved August 31, 2022, from https://www.nia.nih.gov/health/how-alzheimers-disease-treated
Briefing, D. (2021, November 29). 41% of Adulhem patients had brain swelling or bleeding. Advisory Board. Retrieved August 31, 2022, from https://www.advisory.com/daily-briefing/2021/11/29/aduhelm-side-effects
Nania, R. (2022, April 8). Medicare limits coverage of Alzheimer's Drug Aduhelm. AARP. Retrieved August 31, 2022, from https://www.aarp.org/health/medicare-insurance/info-2022/aduhelm-coverage.html
Brent, R. J. (2016, November 14). Life expectancy in nursing homes. Taylor & Francis. Retrieved August 31, 2022, from https://www.tandfonline.com/doi/full/10.1080/00036846.2021.1983138
Stringfellow, A. (2018). Dementia care costs by state: An overview of costs, types of dementia care, and the cost of dementia care by State. Dementia Care Costs by State: An Overview of Costs, Types of Dementia Care, and the Cost of Dementia Care by State. Retrieved August 31, 2022, from https://www.seniorlink.com/blog/dementia-care-costs-by-state-an-overview-of-costs-types-of-dementia-care-and-the-cost-of-dementia-care-by-state
Gallagher, J. (2015, December 16). Low-income alzheimer's patients battle more than the disease. CNS Maryland. Retrieved August 31, 2022, from https://cnsmaryland.org/2015/12/16/low-income-alzheimers-patients-battle-more-than-the-disease/
Tóth, P., Gavurová, B., & Barták, M. (2018). Alzheimer's Disease Mortality according to Socioeconomic Factors: Country Study. International journal of Alzheimer's disease, 2018, 8137464. https://doi.org/10.1155/2018/8137464
Kaltenboeck, A., Mehlman, A., & Pearson, S. D. (2021, April 26). Strengthening the accelerated approval pathway: An analysis of potential policy reforms and their impact on uncertainty, access, innovation, and costs. Retrieved September 1, 2022, from https://icer.org/wp-content/uploads/2021/04/Strengthening-the-Accelerated-Approval-Pathway-_-ICER-White-Paper-_-April-2021.pdf
Young il Lee, Wesley J. Thompson, Chapter 54 - The Vertebrate Neuromuscular Junction, Editor(s): Joseph A. Hill, Eric N. Olson, Muscle, Academic Press, 2012, Pages 775-787, ISBN 9780123815101, https://doi.org/10.1016/B978-0-12-381510-1.00054-5. (https://www.sciencedirect.com/science/article/pii/B9780123815101000545)
Published
How to Cite
Issue
Section
Copyright (c) 2022 Alex Zhu; Sharifa Sahai
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
